| Sep 16 |
Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research
|
| Sep 9 |
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
|
| Sep 5 |
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 20 |
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024
|
| Aug 14 |
Actuate Therapeutics Announces Closing of Initial Public Offering
|
| Aug 13 |
Actuate Therapeutics shares rise 6% following a $22.4M IPO
|
| Aug 13 |
Actuate Therapeutics Announces Pricing of Initial Public Offering
|
